SAPHO Syndrome is a rare condition that affects bones and joints. It causes inflammation in the bones (osteitis) and skin (pustulosis). It often affects the upper chest area, causing thick, hard bone growth (hyperostosis). It can also cause joint pain (synovitis). The exact cause isn't known, but it's thought to be related to inflammation.
Every report comes from a Lived member, sent anonymously.
Have you tried Aleve (Naproxen) for SAPHO Syndrome?
SAPHO syndrome is a rare inflammatory condition that affects bones and joints together with the skin. The name is an acronym for its main features: synovitis (joint inflammation), acne, pustulosis (crops of pus-filled spots), hyperostosis (thickening of bone) and osteitis (inflammation inside bone). The bone inflammation is sterile, meaning it is not an ordinary bone infection, even though it can look like one on scans. Older names include acquired hyperostosis syndrome. The most characteristic sign is pain, swelling and tenderness at the front of the chest, where the collarbones meet the breastbone and the upper ribs. The spine, the joints at the base of the spine (sacroiliac joints), the jaw and joints such as the hips, knees and ankles can also be involved. The most common skin problem is palmoplantar pustulosis, recurring sterile pustules on the palms and soles. Others include severe acne and psoriasis. Not everyone has every feature, and the skin and bone problems often appear at different times. Skin changes can come before the bone pain, follow it by months or years, or never appear, which is one reason the diagnosis is often delayed.
The cause of SAPHO is not known. Researchers think it develops when the immune system overreacts in people with some underlying susceptibility, possibly set off by something in the environment. One suspected trigger is Cutibacterium acnes, a slow-growing bacterium that normally lives on the skin, plays a role in acne and has been found in some bone samples from people with SAPHO. This does not mean SAPHO is a contagious infection, and antibiotics help only some people. SAPHO usually begins in young adulthood or middle age, though it can start in childhood or later life. Severe acne is the more common skin pattern in men, while palmoplantar pustulosis and psoriasis are more common in women. Smoking is strongly linked to palmoplantar pustulosis. SAPHO sometimes occurs alongside inflammatory bowel disease. No single gene has been shown to cause it, and it is not something a person brings on through their own actions.
There is no single blood test or scan that confirms SAPHO. A clinician, usually a rheumatologist working with a dermatologist, looks for the combination of inflammatory bone or joint disease with one of its typical skin conditions, now or in the past. Several sets of diagnostic criteria exist, but none has been fully validated, so experience and judgment matter. Imaging carries much of the weight. MRI can show active inflammation inside bone (bone marrow swelling) before X-rays show anything. A bone scan can reveal several affected areas at once; a symmetrical pattern at the top of the chest, sometimes called the bull's head sign, is typical but missing in many people. CT scans and X-rays show bone thickening and hardening. Blood tests for inflammation, such as the sedimentation rate and C-reactive protein, are raised in only some people and cannot prove or rule out SAPHO. An important part of the assessment is excluding look-alikes. Bacterial bone infection and bone tumors can resemble SAPHO, so a bone biopsy is often needed, especially when only one bone is affected. Psoriatic arthritis and other forms of spondyloarthritis, a family of inflammatory arthritis affecting the spine, are also considered.
No medicine is approved specifically for SAPHO, and there are almost no randomized trials, so treatment relies on case reports, small studies and specialist experience. It is matched to whichever features are most troublesome, bone and joint or skin, and adjusted over time. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as naproxen or ibuprofen, are usually tried first for bone and joint pain. They often help only partly or temporarily, so most people need something more. Short courses of steroids or a steroid injection into an inflamed joint can calm a flare. Long courses of antibiotics such as doxycycline or azithromycin are sometimes tried because of the suspected bacterial trigger, but they help a minority, and the benefit often fades when they stop. Bisphosphonates, bone-strengthening drugs that slow bone turnover, are commonly used for persistent bone inflammation. Pamidronate, given by infusion, is the most studied: in a small trial it reduced bone inflammation on MRI and eased pain and disability, and reports suggest roughly half of people benefit. Methotrexate, a weekly immune-calming medicine, is often used for arthritis in the limbs and for skin disease. When these are not enough, biologic medicines and related targeted drugs used for psoriasis and inflammatory arthritis are tried off-label. Tumor necrosis factor (TNF) inhibitors such as adalimumab (Humira) have the most reported experience, and Janus kinase (JAK) inhibitors, a newer group of immune-targeting pills, also show promising results. The evidence is still limited to individual reports and small series. These drugs lower part of the immune defense, so they raise the risk of serious infection and require screening for tuberculosis (TB) beforehand. Biologics occasionally trigger new psoriasis or other skin flares. Skin disease is treated alongside the bones with creams, light therapy or systemic medicines. Severe acne in SAPHO can be hard to treat. Isotretinoin, a strong acne medicine, is used, but high starting doses have been reported to worsen bone and joint symptoms, so it is often started at a low dose in coordination with the rheumatologist. Methotrexate and isotretinoin can both cause serious birth defects or pregnancy loss, so anyone who could become pregnant needs reliable contraception while taking them and should discuss pregnancy plans before starting. Stopping smoking often improves palmoplantar pustulosis.
SAPHO is usually long-lasting. For some people it comes in flares separated by quieter periods; for others pain is more constant. The course is hard to predict, and the pattern of affected bones and skin can change over the years. Many people find a treatment combination that controls symptoms well, but it often takes several attempts, and medicines may need changing if symptoms return. Bone and joint pain usually has the biggest effect on daily life, limiting sleep, lifting, exercise and work. Visible skin disease on the hands, feet or face can be painful and can affect confidence and social life. Fatigue can be part of the condition. Depression is also more common than in the general population and is treatable, so low mood is worth raising with the care team. Follow-up usually involves a rheumatologist and a dermatologist, with repeat imaging when symptoms change and blood tests to monitor medicines such as methotrexate or biologics. Staying active within comfortable limits and not smoking support both joint function and skin control.
Arrange an evaluation if you have persistent pain or swelling at the front of the chest, spine or other bones, especially if you also have pustules on the palms or soles, severe acne or psoriasis. Tell your care team if symptoms return or spread, or if treatment is not controlling them. Get seen the same day for new swelling of one arm, especially with bluish discoloration or visible veins over the chest or shoulder, because thickened bone near the collarbone can occasionally compress a large vein and lead to a clot. Call 911 if arm swelling comes with sudden shortness of breath or chest pain, which can mean a clot has traveled to the lungs. If you take a biologic, a JAK inhibitor or methotrexate, contact your care team promptly about fever or other signs of infection.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with SAPHO Syndrome is like, what's helped you, or ask the community a question.